Cited by Patients with Hepatitis C Undergoing Direct-Acting Antiviral Treatment Have a Lower SARS-CoV-2 Infection Rate

Changes and Long-Term Effects of the Immune System after COVID-19 Infection DOI

Zhixiong Wu

Theoretical and Natural Science, Journal Year: 2025, Volume and Issue: 69(1), P. 78 - 84

Published: Jan. 15, 2025

Following the pandemic in 2020, physical health has generally declined. All of this is brought on by modifications to body's immune system and consequences sequelae. The current research gap caused neglect COVID-19's after effects. In paper, relationship between changes, complications their conditions was studied, preliminary results harm prevention sequelae were obtained. system's alterations during epidemic infection its are main topics article, including cytokine storms, inflammatory responses, changes cells. At same time, article explores underlying conditions, such as chronic diseases autoimmune diseases, they cause. Through observation analysis later stages epidemic, reasons for general decline people's fitness system. future, it hoped that there will be improvements disease measures diseases.

Language: Английский

Citations

Epidemic within a pandemic: Alcohol‐associated hepatitis and COVID‐19 DOI

Natalie Marlowe,

David Lam,

Suthat Liangpunsakul

et al.

Alcohol Clinical and Experimental Research, Journal Year: 2023, Volume and Issue: 47(10), P. 1883 - 1889

Published: Aug. 9, 2023

There was an increase in alcoholic beverage sales during the peak of COVID pandemic United States. However, little is known about impact SARS-CoV-2 infection among hospitalized alcohol-associated hepatitis (AH) patients.We analyzed available National Inpatient Data (NIS) data from 2020 to determine mortality and healthcare utilization AH patients with without COVID-19 States.We observed a ~15.6% cases 136,620 2019 157,885 2020, significant average 5.5% per annum despite 8.7% decline US hospital admissions over same time span. Men younger than 40 were fastest growing group, 23% 2020. Approximately 1.8% had infection, which significantly worsened (11.4% vs. 4.1%, p < 0.0001). This especially true older concomitant conditions such as clinically apparent cirrhosis, acute renal failure, upper gastrointestinal bleeding, sepsis. also longer length stay (8.6 6.1 days, 0.0001) higher charges ($93,670 $66,283, those COVID-19.Our study highlights rise pandemic. Screening appropriate management excessive alcohol use preventive measures vaccination should be considered reduce morbidity AH.

Language: Английский

Citations

Adjustment of Immunosuppressants to Facilitate Anti-COVID-19 Antibody Production after mRNA Vaccination in Liver Transplant Recipients DOI

Wei‐Chen Lee, Hao‐Chien Hung, Jin‐Chiao Lee

et al.

Viruses, Journal Year: 2023, Volume and Issue: 15(3), P. 678 - 678

Published: March 4, 2023

Liver transplant recipients are immunocompromised and have low immunogenicity to produce antibodies in anti-COVID-19 vaccination. Whether immunosuppressant adjustment could facilitate antibody production mRNA vaccination is undetermined. Our patients were informed temporarily suspend mycophenolate mofetil (MMF) or everolimus (EVR) for 2 weeks during both the 1st 2nd doses of Moderna mRNA-1273 vaccine. A total 183 receiving two vaccine enrolled grouped into tacrolimus monotherapy (MT, n = 41), dual therapy with non-adjustment (NA, 23), single suspension (SS, 19) double (DS, 100) MMF/EVR two-dose 155 (84.7%) had a humoral response vaccines this study. The rates 60.9%, 89.5%, 91.0% 80.5% NA, SS, DS, MT group patients, respectively (p 0.003). Multivariate analysis showed that favorable factors temporary monotherapy, unfavorable deceased donor liver transplantation, WBC count < 4000/uL, lymphocyte 20% trough level ≥ 6.8 ng/mL. In conclusion, two-week anti-proliferation immunosuppressants create window This concept may be applied other vaccinations recipients.

Language: Английский

Citations

Progression of segmental colitis associated with diverticulosis to ulcerative colitis DOI

Akira Hokama

Journal of Gastrointestinal and Liver Diseases, Journal Year: 2024, Volume and Issue: 33(2), P. 285 - 286

Published: June 29, 2024

Gluten does not induce gastrointestinal symptoms in healthy volunteers: the British Broadcasting Company ExperimentTo Editor, While gluten-free diet (GFD) is best treatment for clinical gluten sensitivity (GS) [(e.g.coeliac disease (CD), nonceliac (NCGS)], scientific opinion supports that safe general population [1].However, celebrity/athletic endorsement of GFD has cultivated an image as "unhealthy" [2]."Lifestylers", "free from" or "people who avoid gluten" are individuals a lifestyle choice.American market research [3] found 44% people buy food reasons other than GS, and 65% believe generally healthier.This trend driven worldwide industry from values $1.7bn 2011 to $3.5bn 2016, it forecast reach $4.7bn 2020 [4].The surge popularity also encouraged opposing belief "fad" [2].This unfortunate with CD/NCGS express they taken seriously restaurants, even face dismissive attitudes non-specialist clinicians [5].The drawing clear line between those do benefit needed ground public perspective on these issues.For this reason, conjunction (BBC) we undertook televised experiment.Our hypothesis was giving volunteers (via gluten-containing flour) should cause any symptoms.Participants (who received no financial incentives), recruited by BBC advertising, were ≥18 years, had diagnosed gluten-related disorders followed diets.The experiment aimed recruit 30 subjects divide into two groups; previous data available but NCGS Double Blind Randomised Controlled Trials (DBRCT) have reported symptom changes induced which would carry 89.2% power if observed within group N=15 [6].Participants point care tested (IgA/

Language: Английский

Citations

COVID-19 vaccine updates for people under different conditions DOI

Yi-Jiao Huang,

Weiyang Wang, Yan Liu

et al.

Science China Life Sciences, Journal Year: 2024, Volume and Issue: 67(11), P. 2323 - 2343

Published: July 29, 2024

Language: Английский

Citations

Seroconversion and safety of Covid-19 vaccines in patients with chronic liver disease and liver transplant: A systematic review DOI

Abdel‐Naser Elzouki, Mohamed Nabil Elshafei,

Afia Aziz

et al.

Qatar medical journal, Journal Year: 2023, Volume and Issue: 2023(3)

Published: Sept. 23, 2023

As part of the COVID-19 control strategy, a growing number vaccine portfolios evolved and got fast-tracked through regulatory agencies, with limited examination their efficacy safety in vulnerable populations, such as patients chronic conditions immunocompromised states. Patients liver disease (CLD), cohorts post transplant (LT) particular, were underrepresented determinant trials development, hence paucity data on published literature. This systematic review aims to examine available evidence ascertain effectiveness Covid-19 vaccination CLD those LT.A PubMed (Medline), Google Scholar, Cochrane Library, ScienceDirect from inception until 1st March 2022 was conducted. We included observational studies assessed regarding seroconversion or immunological rate, whereas serious significant adverse effects have been considered outcomes when reported.Studies comprised 45275 patients, performed 11 different countries. Seroconversion rate after mostly primary endpoint, other endpoints like covid-19 related also reported. Twenty-four final analyzed are prospective cohort studies, while four retrospective studies. Twenty-one who underwent LT received Covid vaccine; nine had due various etiologies. The median age range all varied 43-69 years. All at least two doses around 60%. about 92% vaccination. average post-transplant recipients 45% vaccines: Pfizer, AstraZeneca, Moderna, Jansen. Only reported higher 75% 73% third dose vaccine. No studies; most commonly negative effect local injection site pain.The present review, comprising real-world concludes that associated 60% rates LT, respectively. side finding helps resolve uncertainty this patients.

Language: Английский

Citations

Association between antibody responses post-vaccination and severe COVID-19 outcomes: national population-based cohort study in Scotland DOI

C. M. Macdonald, Norah Palmateer, Andrew McAuley

et al.

Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown

Published: May 23, 2023

Abstract Several population-level studies have described individual clinical risk factors associated with suboptimal antibody responses following COVID-19 vaccination, but none examined multimorbidity. Others shown that post-vaccination offer reduced protection to subsequent SARS-CoV-2 infection; however, the level of from hospitalisation/death remains unconfirmed. We use national Scottish datasets investigate association between multimorbidity and testing antibody-negative, examining correlation levels among double-vaccinated individuals. found individuals (≥five conditions) were more likely test antibody-negative 13.37 [6.05 - 29.53] times be hospitalised/die than without conditions. also show a dose-dependent hospitalisation or death, those undetectable at significantly higher (HR 9.21 [95% CI 4.63 18.29]) these serious outcomes compared high levels.

Language: Английский

Citations

Impact of prior SARS-CoV-2 infection on postoperative recovery in patients with hepatocellular carcinoma resection DOI

Dan Fang,

B.K. Gan,

Lei Wu

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 7, 2024

Abstract BACKGROUND The impact of prior SARS-CoV-2 infection on postoperative recovery patients who underwent liver resection for hepatocellular carcinoma (HCC) remains uncertain given the lack sufficient evidence. AIM To investigate (HCC). METHODS Patients were pathologically diagnosed with HCC and elective partial hepatectomy in Guangdong Provincial People’s Hospital between January 2022 April 2023 enrolled this retrospective cohort study. divided into two groups based their history infection. Rehabilitation parameters, including function, incidence complications, hospitalization expenses, compared groups. Propensity score matching (PSM) was performed to reduce confounding bias. RESULTS We included 172 (58 114 without infection) HCC. No significant differences rehabilitation parameters observed After PSM, 58 selected from each group form new comparative Similar results obtained within population after PSM. CONCLUSION Prior does not appear affect rehabilitation, or expenses among hepatectomy.

Language: Английский

Citations

Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland DOI

C. M. Macdonald, Norah Palmateer, Andrew McAuley

et al.

npj Vaccines, Journal Year: 2024, Volume and Issue: 9(1)

Published: June 14, 2024

Several population-level studies have described individual clinical risk factors associated with suboptimal antibody responses following COVID-19 vaccination, but none examined multimorbidity. Others shown that post-vaccination offer reduced protection to subsequent SARS-CoV-2 infection; however, the level of from hospitalisation/death remains unconfirmed. We use national Scottish datasets investigate association between multimorbidity and testing antibody-negative, examining correlation levels among double-vaccinated individuals. found individuals ( ≥ five conditions) were more likely test antibody-negative 13.37 [6.05-29.53] times be hospitalised/die than without conditions. also show a dose-dependent hospitalisation or death, those undetectable at significantly higher (HR 9.21 [95% CI 4.63-18.29]) these serious outcomes compared high levels.

Language: Английский

Citations

Differential expression of NFκB p65 contributes to the fate of liver cells in acute liver failure DOI

Ajay Singh,

Premashis Kar,

Bhudev C. Das

et al.

Journal of Gastrointestinal and Liver Diseases, Journal Year: 2024, Volume and Issue: 33(2), P. 284 - 285

Published: June 29, 2024

Language: Английский

Citations